Brasfield K H
School of Pharmacy, Medical College of Virginia, Richmond.
Nurs Clin North Am. 1991 Sep;26(3):651-63.
Of the antidepressants on the US market, only alprazolam and trazodone have questionable antidepressant efficacy. Because all other antidepressants are equally effective in major depressive illness, drugs are used based on particular patient characteristics matched with individual antidepressant drug profiles. In general, antidepressant plasma concentration monitoring is only clinically useful with some of the TCAs. Nortriptyline, imipramine, and desipramine have demonstrated the highest correlation between clinical response and plasma concentration. MAO inhibitors are useful but require a reliable patient who can comply with dietary restrictions. Maprotiline and amoxapine are not first- or second-line antidepressants. Clomipramine and fluoxetine offer unique properties that make them first- or second-line antidepressants for particular patients. There are significant drug interactions with antidepressants that should be avoided.
在美国市场上的抗抑郁药中,只有阿普唑仑和曲唑酮的抗抑郁疗效存疑。由于所有其他抗抑郁药在重度抑郁症中疗效相当,因此根据与个体抗抑郁药特性相匹配的特定患者特征来使用药物。一般来说,抗抑郁药血浆浓度监测仅对某些三环类抗抑郁药在临床上有用。去甲替林、丙咪嗪和地昔帕明已证明临床反应与血浆浓度之间的相关性最高。单胺氧化酶抑制剂有用,但需要可靠且能遵守饮食限制的患者。马普替林和阿莫沙平不是一线或二线抗抑郁药。氯米帕明和氟西汀具有独特的特性,使其成为特定患者的一线或二线抗抑郁药。抗抑郁药存在显著的药物相互作用,应予以避免。